外用环孢素A联合CTLA4Ig延长异体移植鼠耳存活的研究

目的　探讨局部外用环孢素 A(Cs A)联合细胞毒性淋巴细胞相关抗原 4融合蛋白 (CTL A4 Ig)对异体复合组织移植的免疫抑制及诱导免疫耐受的作用。方法　建立吻合血管的同种异体大鼠耳廓移植模型 ,术后在移植耳皮肤表面外涂 Cs A并联合 CTL A4 Ig腹腔注射治疗 ,观察移植物的排斥反应及存活时间 ,检测移植后受体血清白细胞介素 - 2 (IL- 2 )含量变化。结果　对照组平均存活时间为 (7.8± 1.7)天 ;单纯用 Cs A治疗组为 (15 .2± 1.9)天 ,单纯CTL A4 Ig治疗组为 (16 .6± 2 .1)天 ;Cs A +CTL A4 Ig联合治疗组为 (2 8.8± 3.5 )天 ,与其它各组相比均有统计学意义 (P<0 .0 1) ;且联合治疗组的受体血清 IL - 2含量最低 ,尤以第 5、7天为著 ,与其它各组相比有统计学意义 (P<0 .0 1)。结论　局部外用 Cs A联合 CTL A4 Ig能有效抑制异体复合组织移植排斥反应 ,显著延长移植物存活时间。     

苦杏仁苷对肾脏移植大鼠存活情况的影响

目的：研究苦杏仁苷（amygdalin）是否能增加肾移植大鼠的存活时间,及评估苦杏仁苷与环孢素（cyclosprin,CsA）联合用药时对大鼠肾移植的临床疗效。方法：20只肾移植大鼠随机分为4组：空白对照组、苦杏仁苷组、CsA组和苦杏仁苷＋CsA组,观察其存活时间及移植肾病理变化。结果：空白对照组存活时间最短（5.44±0.51）d,其与苦杏仁苷组（6.29±0.74）d比较具有统计学差异（P〈0.05）;苦杏仁苷＋环孢素组存活时间最长（11.84±0.76）d,其与环孢素组（9.26±0.74）d比较亦具有统计学差异（P〈0.05）,移植肾组织病理上各组均有不同程度的急性排斥反应,并具有各自的病理特点。结论：苦杏仁苷可在一定程度上延长肾移植大鼠的存活时间;苦杏仁苷和环孢素联合用药效果优于单用环孢素,其联合用药更能延长肾移植大鼠的存活时间。     

小剂量环孢素A联用细胞毒T淋巴细胞A4-Ig治疗器官移植排斥反应

目的　研究小剂量环孢素A(CsA)联用细胞毒T淋巴细胞A4 Ig(CTLA4 Ig)治疗器官移植排斥反应的效果。　方法　采用Ono′s方法建立大鼠心脏移植排斥反应动物模型 ,将实验动物分为 4组。A组 :对照组 ,未给予任何治疗 ;B组 :腹腔内注射CsA ,10mg·kg-1·d-1,连续 7d ;C组 :术后第 2天 1次性注射CTLA4 Ig 10 0 μg ;D组 :术后 1～ 7d连续腹腔内注射CsA ,2mg .kg-1.d-1,术后第 2天加用CTLA4 Ig 5 0 μg。观察移植心脏存活天数及术后IL 2含量和组织学变化。　 结果　A、B、C、D 4组大鼠移植心脏存活时间分别为 ( 7 2± 0 7)、( 19 4± 2 1)、( 3 1 6± 1 8)和 ( 2 4 6± 2 1)d ,与对照组相比 ,各治疗组大鼠心脏存活时间明显延长 ,差异有显著性意义 (q =3 2 7 83 ,P <0 0 5 ) ,D组与C组相比差异无显著性意义 (q =1 86,P >0 0 5 ) ;各治疗组术后IL 2含量明显减低 ,与对照组相比差异有非常显著性意义 (q=9 82 ,P <0 0 1) ;A、B、C和D组排斥反应分级分别为Ⅳ、Ⅲ、Ⅰ和Ⅰ级。　结论　CTLA4 Ig抗排斥反应能力比CsA强 ,小剂量CsA联合使用CTLA4 Ig能增强治疗排斥反应疗效 ,两者具有正协同作用。     

Discordant heart xenografts in the rat. Additional effect of plasma exchange and cyclosporine, cyclophosphamide, or splenectomy in delaying hyperacute rejection

Natural antidonor antibodies are known to play a prominent role in hyperacute xenograft rejection. The aim of this work was to devise an experimental protocol to prolong the survival time of guinea pig heart xenografts transplanted into rats. A technique of continuous plasma exchange adapted to small animals was used to remove the natural cytotoxic antibodies from the recipient prior to the transplantation. In some experiments, cyclosporine (CsA), cyclophosphamide (CY), or splenectomy were associated with the plasma exchange. In this highly discordant xenogenic donor-recipient combination, the mean graft survival time in nontreated rats was 16 min. When an exchange of 1.5 plasma volume was performed 24 hr before the transplantation, no prolongation of the graft survival time was observed. When CsA, CY, or splenectomy were associated with the plasma exchange, the graft survival time was significantly increased by more than 2500% (up to 418 min with CsA). When used isolately, none of these 3 immunosuppressive methods was able to prolong the graft survival time. Natural cytotoxic antibodies were monitored by a complement-mediated cytotoxicity assay. After a plasma exchange, the titers decreased from 1:16-1:32 to 1:1-1:2. When no immunosuppressive method was associated with the plasma exchange, the antibodies returned to their initial level within the 24 hr that preceded the transplantation, and the graft was rejected as in nontreated animals. When an immunosuppressive method was associated with the plasma exchange, and particularly in the case of CsA, the titers remained low, and the hyperacute rejection was delayed. Therefore, it can be concluded that plasma exchanges, associated with CsA, are an efficient experimental protocol in the rat to increase the survival time of guinea pig heart xenografts. The effect of the treatment is correlated with the decrease in natural cytotoxic antidonor antibodies.     

A comparison of heterotopic and orthotopic intestinal transplantation in rats

Two surgical techniques are commonly used for small intestinal transplantation: heterotopic (accessory) intestinal grafting (HIT), where the small bowel is initially defunctioned with restoration of intestinal continuity at a later date, and orthotopic (in continuity) intestinal grafting (OIT), where the small bowel is immediately anastomosed to the native intestine. The present experiments were undertaken to compare the advantages and disadvantages of these two surgical models. Graft barrier function (intestinal permeability), intestinal histology, and graft survival were evaluated after heterotopic and orthotopic intestinal transplantation in the following groups of rats: group 1: isografts, group 2: untreated allografts, group 3: low-dose cyclosporine-treated allografts (subcutaneous CsA 2 mg/kg/day), and group 4: high-dose CsA-treated allografts (subcutaneous CsA 4 mg/kg/day). Intestinal permeability was consistently higher after HIT than OIT in all of the groups (ANOVA; P less than 0.01). Histological evidence of rejection appeared earlier after HIT than OIT (HIT 5th postoperative day (POD); OIT 7th POD; P less than 0.05). The mean survival of untreated allografts was longer after HIT than OIT (HIT 15.7 +/- 6 days, OIT 9.2 +/- 1 days, P less than 0.05). The rats treated with low-dose CsA after OIT lost weight and died of rejection after a mean survival time of 17.7 +/- 2 days, while the rats treated with low-dose CsA after HIT remained well until sacrifice on POD 28 (P less than 0.01). The rats with isografts and rats with allografts treated with high-dose CsA remained well after HIT and OIT until sacrifice on the 28th POD. These data suggest that nutrients and other factors in the succus entericus may improve gut barrier function and delay the onset of rejection after OIT. However, rejection of the orthotopic intestinal graft is usually fatal, while rejection of the heterotopic graft is often surprisingly well tolerated. These factors must be taken into consideration when choosing a surgical technique for intestinal transplantation in humans.     

延长非协调性异种心脏移植存活时间的研究

目的 寻找延长非协调性异种心脏移植存活时间的方法。方法 实验分Ａ、Ｂ、Ｃ、Ｄ４组,将异种心脏（豚鼠－大鼠）移植于颈部。Ａ组：移植前受体用眼镜蛇蛇毒因子（ＣＶＦ）１５０ｕｇ．ｋｇ－１．ｄ＾－１,腹膜腔内注射（ｉ．ｐ）,每天分２次,相隔３ｄ,共４次;Ｂ组：在Ａ组的基础上,移植前１ｈ加用己酮可可碱（ＰＴＸ）５０ｍｇ／ｋｇ（ｉ．ｐ）,然后每隔６ｈ按２５ｍｇ／ｋｇ（ｉ．ｐ）至发生排斥反应为止;Ｃ组：在Ａ组的     

大鼠原位肝移植术后急性排斥反应中 Fractalkine的表达及意义

目的利用直视下套入式吻合肝动脉加袖套法吻合门静脉建立的大鼠全血供肝移植模型,研究同种异体大鼠肝移植术后早期急性排斥反应中Fractalkine（Fkn）的表达情况。方法制备SD-Wistar大鼠全血供肝移植模型,随机分为两组,每组20只。对照组：于移植术后第1天开始腹腔内注射生理盐水（3ml/kg）;实验组：于移植术后第1天开始腹腔内注射环孢素A（3mg/kg）。术后观察大鼠一般情况,并于第3、5及7天分别处死5只大鼠,取肝脏标本,观察移植肝组织排斥反应强度（rejection activity index,RAI）及Fkn表达情况;余大鼠观察生存时间。结果对照组存活18只,实验组存活19只。实验组较对照组术后一般情况好,存活时间为19.50±4.51d,与对照组7.60±1.60d比较,差异有统计学意义（P〈0.05）。组织学观察：对照组移植肝小叶结构清楚,汇管区增大,大量淋巴细胞浸润;实验组移植肝组织RAI明显降低。术后第3、5及7天,对照组RAI为3.80±0.35、5.90±0.87及7.50±1.30,实验组为3.10±0.21、3.90±0.41及4.50±0.52。两组术后第7天RAI比较差异有统计学意义（P〈0.01）。免疫组织化学观察：两组移植肝组织中均见细胞浆或细胞膜有棕色颗粒的Fkn表达,但实验组表达较弱。术后第3、5及7天,对照组Fkn细胞数为8.20±0.57、21.30±3.30及25.70±4.91,实验组分别为8.30±0.56、10.30±0.67及11.70±1.23;两组第5、7天比较差异有统计学意义（P〈0.01）。结论Fkn参与了同种异体大鼠肝移植急性排斥反应,可作为诊断大鼠肝移植急性排斥反应发生的指标之一。环孢素A可以通过抑制Fkn表达来抑制排斥反应发生的强度。     

氨基胍与环孢素A联用对大鼠心脏移植后急性排斥反应的影响

目的：探讨氨基胍与环孢素A联用对同种大鼠心脏移植后急性排斥反应的影响。方法：受体SD大鼠心脏移植后分为4组：（1）对照组：术后不作任何处理;（2）低剂量环孢素A（CsA)组;术后0－7d肌肉注射CsA2mg.kg^-1.d^-1;（3）氨基胍（AG）组：术后0－7d皮下注射AG600mg.kg^-1.d^-1;（4）低剂量CsA加AG组;术后0－7d肌肉注射CsA2mg.kg^-1.d^-1及皮下注射AG600mg.kg^-1.d^-1。术后4d测定急性排斥反应时移植心的诱生型一氧化氮合酶（iNOS)的表达及血清一氧化氮（NO）含量,并观察移植心存活时间。结果与低剂量环孢素A组相比较,低剂量环孢素A与氨基胍联用组不仅显著地抑制移植心iNOS表达与NO产生（P＜0．05）;而且显著地减轻急性排斥反应（P＜0．01）,延长了移植心存活时间（P＜0．05）。结论低剂量环孢素A与氨基胍联用,协同抑制急性排斥反应时移植心iNOS活性及NO产生;显著地延长移植物存活时间。     

Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan

INTRODUCTION: This study compared the efficacy and safety of a tacrolimus (TAC)-based with a cyclosporine (CsA)microemulsion-based immunosuppressive regimen in primary cardiac transplantation. METHODS: Heart recipients were randomly assigned to receive either TAC or CsA regimen after sequential induction with rabbit anti-thymoglobulin. Endomyocardial biopsies were performed at weeks 1, 2, 3, and 4 and months 2, 3, and 6. RESULTS: Among 21 adult patients (TAC, 11; CsA, 10) in this study, patient survival rates were 100% in both groups at the end of 6 months. One patient (9%) in the TAC group experienced acute rejection (ISHLT > or = 1B) versus 6 patients (60%) in the CsA group (P = .02). The effects on hematology, biochemistry, cytomegalovirus infection, and hemodynamics were similar in both groups except for better lipid profiles in the TAC group. There were no significant differences in severe adverse events. CONCLUSION: The TAC-based regimen had a lower risk of acute rejection compared with CsA in heart transplant recipients. The safety profiles were similar in both groups. Therefore, TAC is an alternative to CsA as a primary maintenance immunosuppressant in heart transplantation.     

Tolerance of rat liver allografts induced by short-term selective immunosuppression combining monoclonal antibodies directed against CD25 and CD54 with subtherapeutic cyclosporine

BACKGROUND: Our purpose was to develop and evaluate protocols for selective immunosuppression after liver transplantation using the monoclonal antibodies (mAbs) NDS-61, directed against the interleukin-2 receptor (CD25), and 1A29, directed against the intercellular adhesion molecule-1 (CD54), in combination with subtherapeutic cyclosporine (CsA). METHODS: Orthotopic rat liver transplantation (ORLT) was performed in a DA-to-LEW strain combination. Immunosuppression was administered from day 0 to +13. Functional parameters such as survival time, body weight, and serum bilirubin levels were measured and the liver grafts were evaluated histologically. RESULTS: A stepwise tapering of CsA from 3 to 0.25 mg/kg/day reduced the long-term survival rate. All animals died at a CsA dosage of 0.25 mg/kg/day, which was therefore defined as subtherapeutic. Monotherapy with the anti-CD25 mAb was performed at dosages of 600 and 1800 microg/kg/day. The lower mAb dosage resulted in a long-term survival rate of 12% and was defined as subtherapeutic. The combination therapy of CsA (0.25 mg/kg/day) and anti-CD25 mAb (600 microg/kg/day) produced a synergistic effect and led to a long-term survival rate of 84%. This survival rate was significantly higher than those after either CsA (P<0.005) or anti-CD25 mAb (P<0.001) monotherapy. Both dosages (10 and 30 microg/kg/day) of anti-CD54 mAb monotherapy as well as anti-CD54 mAb combined with a subtherapeutic dosage of CsA were ineffective in preventing acute allograft rejection. The addition of anti-CD54 mAb (30 microg/kg/day) to combined CsA plus anti-CD25 mAb therapy (triple therapy), however, increased the long-term survival rate to 100%. In the triple therapy group there was no rejection process in the liver allografts at any time, and donor-specific tolerance could be shown by donor-specific and third-party heterotopic heart transplantation. CONCLUSIONS: The synergistic action of subtherapeutic CsA plus anti-CD25 mAb NDS-60 could be demonstrated, whereas anti-CD54 mAb only had a positive effect in a triple therapy group. Triple therapy prevented both acute and chronic rejection and induced donor-specific tolerance.     

移植合剂治疗胰腺移植排斥反应的实验研究

目的 :探讨移植合剂在胰腺移植排斥反应中的作用及其机理。 方法 :建立大鼠全胰十二指肠移植模型 ,使用移植合剂和环孢菌素A(cyclosporinA ,CsA)进行治疗 ,观察二者及二者结合应用后各鼠移植胰腺有功能存活时间 ,血清胰岛素水平 ,外周血T淋巴细胞亚群和胰、肝、肾的组织病理学改变。 结果 :移植合剂可以延长移植胰有功能存活时间 (P <0 0 5 ) ;对CD3+T细胞和CD8+T细胞有显著的抑制作用 (P <0 0 1) ;移植合剂与亚治疗量CsA合用后可以达到治疗量CsA的效果且无肝、肾毒性。 结论 :移植合剂对胰腺移植的排斥反应有抑制作用 ,而且与CsA具有一定的协同作用     

急性排斥反应时Fractalkine及其受体在移植心脏中的表达

目的　探讨急性排斥反应过程中Fractalkine(FKN)及其受体CX3CR1在移植心脏局部表达的意义及环孢素A(CsA)对它们的影响。　方法　施行大鼠异位心脏移植术 ,移植大鼠分为 3组 ,每组 45只 ,对照组 5只。SD大鼠间的移植为同系移植组 (A组 ) ,Wistar至SD大鼠的移植分为未用CsA干预组 (B组 )及CsA干预组 (C组 ) ,健康SD大鼠为对照组。采用RT PCR方法检测排斥反应中移植心脏局部FKNmRNA的表达水平 ,免疫组化方法检测FKN和CX3CR1的蛋白表达水平。　结果FKNmRNA与蛋白在A组各时间点和对照组均呈低水平表达 ;在B组的表达变化与急性排斥反应的进程相关 ,术后第 7天FKNmRNA表达上调至峰值 (0 8± 0 2 6) ;C组应用CsA后 ,FKNmRNA表达峰值显著低于B组 (t=2 3 90 ,P <0 0 5 )。FKN和CX3CR1蛋白分别定位于移植心脏血管内皮细胞及间质浸润的单个核细胞中。　结论　急性排斥反应过程中 ,FKN及其受体CX3CR1表达上调 ,与移植物间质单个核细胞浸润密切相关 ;抑制FKN CX3CR1通路的活化可能是CsA发挥作用的又一分子免疫学机制     

Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model

The efficacy of local delivery of aerosol cyclosporine (CsA) for prevention of lung rejection was compared with the intramuscular route (IM) in a fully allogeneic rat model (BN/LEW) of lung transplantation (LTx). Control rats (group 1, n = 6) received no CsA after LTx. Rats in group 2 (n = 10) received 4 doses of CsA in olive oil (25 mg/kg) intramuscularly starting on postoperative day (POD) 0. Group 3 (n = 9) was treated with aerosolized CsA for 3 h/day for 7 days starting on POD 0. All animals were sacrificed on POD 6. Transplanted lungs were graded histologically in a blind manner on a 0-4 scale. Control animals all showed grade 4 rejection. i.m. CsA therapy reduced lung rejection with a rejection grade of 1.8 +/- 0.35 (mean +/- SD) but was associated with a 50% incidence of pneumonia. Aerosol CsA provided better control of rejection with a rejection grade of 1.2 +/- 0.4 (group 3 vs. group 2: P less than 0.05 Wilcoxon) and none of these animals had penumonia. Trough blood levels of CsA were significantly lower in the group treated with aerosolized CsA when compared with the IM group (P less than 0.05). Therefore we conclude that: (1) aerosol CsA is effective in preventing lung allograft rejection following lung transplantation in rats, and (2) local delivery of aerosol CsA is superior to the i.m. route because better control of rejection is achieved with a lower systemic delivery of CsA.     

延迟性异种移植排斥反应的病理特征及IgG的作用

目的利用小鼠→大鼠心脏移植模型，探讨延迟性异种移植排斥反应(DXR)的病理特征及IgG的作用。方法将移植大鼠随机分成4组对照组(A组，n＝6)；环孢素A(CsA)组(B组，n＝6)，CsA每2日用药1次，每次20mg/kg，自移植当日(day0)起使用；环磷酰胺(CyP)组(C组，n＝6)，移植前1d给予CyP40mg/kg，自移植后第1天起每2日用药1次，每次20mg/kg；CsA加CyP组(D组，n=5)。血清IgG水平用ELISA法测定；C     

不同免疫治疗方案诱导大鼠原位肝移植免疫耐受的实验研究

目的 观察抗CD-40L单抗加小剂量CsA联合免疫治疗对肝移植大鼠受体免疫耐受诱导的作用.方法 在建立稳定大鼠肝移植模型的基础上,将肝移植模型分为5组.A组为SD→SD对照组;B组为SD→Wistar对照组,A,B组术后不用任何治疗措施;C组为SD→Wistar,术后用CsA1～5 d;D组为SD→Wistar,术后用CsA 1～5 d加抗CD-40L(CD-154)单抗0～2d;E组为D组+术前供体特异性输血(DSBT).观察受体存活时间、移植肝病理改变以及术后外周血中细胞因子的变化.结果 A,D,E组受体大鼠存活时点(均>60 d)均明显长于B组和C组.D,E组移植肝急性排斥反应明显减轻.B组IL-2和IFN-γ的血清水平显著高于其余各组(P＜0.05).B,C,D,E 4组IL-4和IL-10较A组均有明显增加,尤其D,E组的IL-10表达较B组显著增高(P＜0.05). 结论 抗CD-40L单抗加小剂量CsA(伴或不伴DSBT)联合免疫治疗,可有效延长肝移植大鼠受体生存时间、减轻急性排斥反应并诱导Th2类细胞因子的高水平表达,有助于受体和移植肝的长期存活.     

Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation

BACKGROUND: Severe rejection of small bowel transplantation (SBTx) has been ascribed to abundant lymphoid tissues in the small intestine without well-established evidence. However, the role of donor lymphocytes in rejection is still unclear. The novel immunosuppressant, FTY720, is reported to transfer peripheral blood lymphocytes (PBLs) to lymphoid tissues such as mesenteric lymph nodes (MLNs) and Peyer patches (PP). In the present study, the number of donor lymphocytes in the graft was increased by FTY720, and the influence on rejection was studied in a rat model. Furthermore, the number of the PBL of recipient was decreased by FTY720 before SBTx and the effect on rejection was examined. MATERIALS AND METHODS: Orthotopic total SBTx was performed in Brown-Norway and Lewis rats. In the donor pretreatment study, FTY720 was administrated to donor rats 24 h prior to harvesting to increase the number of graft lymphocytes (FTY donor-pretreated group). In contrast, MLNs were surgically removed from the grafts to decrease the number of graft lymphocytes (MLN-resected group). In the recipient pretreatment study, FTY720 was administrated to recipient rats 24 h before SBTx to decrease recipient PBL (FTY group). In contrast, a subclinical dose of cyclosporine A (CsA) was administrated after SBTx (CsA group). Rats were administrated preoperative FTY720 combined with post-SBTx CsA (FTY+CsA group). Graft survival, pathology, lymphocyte count, and subtype were examined. RESULTS: In the donor pretreatment study, pretreatment with FTY720 did not enhance graft rejection. MLN resection did not prolong graft survival. In the recipient pretreatment study, FTY720 caused a significant reduction in the number of infiltrating lymphocytes in the graft, as well as the percentage of recipient CD4+ and CD25+ cells within the graft. FTY720 and CsA synergistically prolonged graft survival. CONCLUSION: SBTx rejection correlated with the number of recipient PBL, and not with the number of donor lymphocytes transplanted together with the graft. The pretreatment of the recipient with FTY720 was effective in the case of combined use of the low-dose postoperative CsA.     

延长大鼠异种心脏移植后存活时间的实验研究

目的　研究如何延长大鼠异种心脏移植后的存活时间。方法　实验分为A、B、C、D四组。A组 :移植术前 12、8、4、0d及 10、6、2、0d分别将脾细胞 1× 10 8个 ,抗血清 0 .2ml静脉注入受体大鼠 ;B组 :在A组的基础上 ,加用中华眼镜蛇毒 (CCV) 0 .2mg·kg-1·d-1,术前 3d至术日腹腔注射。C组 :在B组的基础上 ,加用环孢素A(CsA) 10mg·kg-1·d-1、环磷酰胺 (Cy) 2 0mg·kg-1·d-1,术前 12d开始至术日腹腔注射。D组 :在C组的基础上 ,加用抗巨噬细胞和抗自然杀伤细胞单克隆抗体 2 5 0 μg·kg-1·d-1,术前 12d开始至术日腹腔注射。结果　A、B、C、D四组移植心脏分别存活 (0 .32± 0 .12 )h ,(2 5 .6± 9.6 )h、(48.6± 10 .4)h和 (72 .4± 2 1.7)h ;术日各组IgG均下降 ,尤以C、D组下降明显 ,与A、B组比较 ,差异有显著性 (P <0 .0 5 )。结论　术前静脉注射供体脾细胞及抗血清 ,尤其与CCV、CsA、Cy合用 ,能显著抑制IgG的产生 ,延长移植心脏的存活时间。     

Experimental study on the effect of ursodeoxycholic acid in liver transplantation]

We investigated the effects of combination of cyclosporine A (CsA) and ursodeoxycholic acid (UDCA) in order to reduce hepatopathy caused by host-versus-graft-reaction (HVG reaction). DA/S1c rats were used as donors, and LEW/Sea rats were used as recipients in orthotopic liver transplantation. The liver transplanted rats were divided to four groups as follows; group A was control that was not given CsA nor UDCA, group B was given CsA alone, group C was given UDCA alone and group D was given combination of CsA and UDCA. These groups were compared and evaluated in case of same dose of CsA that was administered with or without UDCA. The survival periods of group D were significantly longer than those of group B. Blood biochemical levels in group D were significantly lower than those of group B. Histological study of the liver graft of group D showed that destruction of hepatic structure was mild in comparison to that of group B. It was demonstrated that the combination of low dose of CsA and UDCA could prevent hepatopathy due to HVG reaction. These results suggested that addition of UDCA to CsA would be able to reduce the dose of CsA in clinical liver transplantation.     

细胞因子在心脏移植急性排斥反应中的表达及其作用机理

目的观察同种大鼠心脏移植急性排斥反应中,局部细胞因子网络的变化及其机理.方法健康雄性Wistar大鼠(受体)和SD大鼠各48只,将接受移植心脏的Wistar大鼠分4组,每组12只.A组对照组;B组抗白介素2单克隆抗体(IL-2Mab)组;C组环孢菌素A(CsA)组;D组IL-2Mab加CsA组.4组大鼠分别静脉给予生理盐水、抗白介素2单克隆抗体及口服CsA、静脉给予抗白介素2单克隆抗体加口服CsA,采用改良的移植术式建立移植模型.常规监测排斥反应发生情况.应用RT-PCR的方法于术后第1、3、5、7、9、11、14天动态检测移植物局部细胞因子IL-1β、IL-2、CD25、IL-4、IL-5、IL-6、IL-10、TNFα、IFNγ的表达水平.结果移植心脏存活时间,A组为(8.3±1.7)d;B组为(29.2±7.1)d;C组为(26.4±5.7)d;D组为(55.0±11.6)d.B、C、D组移植心脏存活时间显著延长,与A组相比,差异有极显著性意义(P＜0.01).存活时间较长的移植心脏的淋巴细胞浸润和心肌坏死的程度比存活时间较短的心脏明显减轻.IL-1β的表达在各组均较高;IL-4、IL-5、IL-6、IL-10的表达水平在移植心脏存活时间较长的组较高;而IL-2、CD25、IFN-γ、TNFα的表达则相对较低;4组相比差异有显著性意义(P＜0.05).结论细胞因子网络在心脏移植排斥反应中发生了相应的变化,并与干预的因素及移植物存活时间有密切的关系.IL-2Mab、CsA联合用药促使TH1类细胞因子向TH2类细胞因子整体偏离,这种免疫偏离使移植心脏存活时间显著延长.